ASSET PURCHASE AGREEMENTAsset Purchase Agreement • November 17th, 2014 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 17th, 2014 Company IndustryThis ASSET PURCHASE AGREEMENT, dated November 6, 2014 (the “Agreement”), is by and among Amarantus Bioscience Holdings, Inc., a Nevada corporation (“Amarantus”), Regenicin, Inc., a Nevada corporation (“Regenicin”), Clark Corporate Law Group, LLP (fka Cane Clark, LLP, hereinafter “CCLG”), and Gordon & Rees, LLP (“Gordon & Rees”). The parties identified above are sometimes hereinafter individually referred to as a “Party” and collectively as the “Parties”.
OPTION AGREEMENTShare Purchase Agreement • November 17th, 2014 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 17th, 2014 Company Industry JurisdictionTHIS SHARE PURCHASE AGREEMENT (the “Agreement”) is made effective as of November [*], 2014 (the “Effective Date”), among Amarantus Bioscience Holdings, Inc., a Nevada corporation (the “Purchaser”) and Lonza Walkersville, Inc., the sole shareholder of the Company (the “Seller”).